Document:

<PAGE>

December 21, 1998

Uli Hacksell, Ph.D.

Dear Uli:

As discussed, I am pleased to offer you the position of Executive Vice
President, Drug Discovery of ACADIA Pharmaceuticals Inc. I firmly believe that
with your joining our team, ACADIA Pharmaceuticals will have the potential to
not only quickly surpass such short term goals as completing additional
significant corporate partnerships and a successful public offering, but that we
will be able to flourish in facing the challenges to be met in the years ahead
as we build an extremely valuable, technology driven, integrated drug discovery
company. All of us associated with ACADIA Pharmaceuticals look forward to
working with you. The terms of our offer are as follows:

1.       Your title will be Executive Vice President, Drug Discovery and you
         will report to Mark Brann, President and Chief Scientific Officer.
         You will be based at our headquarters in San Diego and be a key
         member of the senior management team. You will be responsible for
         leading ACADIA's worldwide discovery research efforts, including
         pharmacology and chemistry. You agree to devote all of your business
         time, attention and energies to the business of the Company.

2.       Your initial annual salary will be $212,835, subject to adjustment as
         determined by the Board as of January 1 of each year.

3.       You will be eligible to receive an annual bonus with a target of 20% of
         the base salary you receive in each calendar year payable within 90
         days of the end of such Calendar year. The amount of the annual bonus
         will be determined by the Board of Directors based upon your individual
         performance and the financial performance of the Company.

4.       The Company will also provide you a signing bonus of $75,000 payable
         immediately after your beginning employment with ACADIA Pharmaceuticals
         Inc. You agree to return such bonus to the Company if you voluntarily
         terminate your employment within one year of the start date of your
         employment.

5.       Naturally, what I consider to be the most important part of your
         compensation is your participation in the Company's stock option plan.
         You will receive stock options that will vest 25% after 12 months of
         employment with additional vesting of 1/48% after each additional month
         of employment through your 48th month of employment with the

<PAGE>

         Company. The stock options that you will be entitled to, subject to the
         aforementioned vesting schedule and other terms of the plan, will be
         equal to options to purchase 200,000 shares of common stock of the
         Company. The exercise price at which these options will be issued will
         be equal to the fair market value of the common shares of the Company
         at the date of grant of the options, which will be the start date of
         your employment. In the event the company is acquired or completes an
         Acquisition Event as defined in the Company's 1997 Stock Option Plan,
         any unvested options you then hold will be immediately vested, subject
         to your continued employment for a period of at least six months
         following completion of the Acquisition Event if so requested by the
         Company. Enclosed is a copy of the ACADIA Pharmaceuticals 1997 Stock
         Option Plan.

6.       The Company will also pay for your relocation costs, including
         customary closing costs, legal fees, real estate broker fees, house
         hunting trips, temporary housing, movement of household goods, and
         related costs and any necessary tax gross-up payments, but up to a
         total cost to the Company not to exceed $100,000. You agree to
         reimburse the Company one half of the total relocation costs paid by
         the Company if you voluntarily terminate your employment within one
         year of the start date of your employment. In addition, the Company
         will provide you with a loan of up to $100,000 to help facilitate the
         purchase of a primary residence in San Diego. Such loan will bear
         interest at the prime rate, have a security interest in the shares
         underlying your stock options and will be due and payable at the end of
         four years, or earlier in the event of termination of your employment.

7.       In the event the Company terminates your employment, other than for
         cause as defined below, you will receive severance in the form of the
         continuation of your salary for the one year period following the
         termination of your employment plus the benefits you were receiving at
         the time of your termination (subject to the terms of the Company's
         benefit plans).

         For purposes of the above, "cause" for termination shall be deemed to
         exist upon (a) a good faith finding by the Company of material failure
         of the Employee to perform his assigned duties for the Company,
         dishonesty, gross negligence or other material misconduct, or (b) the
         conviction of the Employee of, or the entry of a pleading of guilty or
         nolo contendere by the Employee to, any crime involving moral turpitude
         or any felony.

8.       You will be provided all of the standard United States company
         benefits, including four weeks paid vacation, health and dental
         insurance, group term life and accidental death and dismemberment
         insurance, group disability insurance, travel accident insurance, and
         the ability to participate in the Company's 401k plan which includes
         matching of employees' contributions to the plan up to 5% of your
         compensation (salary and bonus), subject to the limitations imposed by
         sections 401(a)(17), 404(1) and 402(g)(1) of the Internal Revenue
         Service Code. Enclosed is information regarding the Company's various
         benefit programs.

<PAGE>

9.       As a condition of your employment you will be required to agree to and
         sign the Company's standard Disclosure and Inventions Agreement, a copy
         of which is attached.

10.      The start date for your employment will be January 11, 1999 or other
         mutually agreeable date.

11.      As you realize, this offer is contingent on your having the appropriate
         authorization to work in the United States. If you currently do not
         have the right to work in the United States, and should reasonable
         efforts by both you and on the part of the Company fail to obtain such
         right within a reasonable period of time, then you agree to explore
         with the Company other suitable alternatives for employment until such
         authorization can be obtained, including, but not limited to, your
         being based out of our Copenhagen subsidiary.

Uli, we hope the provisions as outlined above address all of the relevant
issues. I am very confident that your joining the ACADIA team will prove
extremely beneficial to both you and the Company and its shareholders. If you
have any questions, please do not hesitate to call me at the office or at home,
my home number is 1-(619) 990-8474. We would appreciate receiving your response
to this offer by December 24, 1998.

Sincerely yours,

/s/ Mark R. Brann

Mark R. Brann, Ph.D.
President and Chief Scientific Officer

I accept your offer to become Executive Vice President, Drug Discovery of ACADIA
Pharmaceuticals Inc. in accordance with the terms included above:

Signature: /s/ Uli Hacksell                        Date: December 23, 1998
         ------------------------------------          -------------------------
                Uli Hacksell<PAGE>

                              EMPLOYMENT AGREEMENT

         THIS EMPLOYMENT AGREEMENT (the "AGREEMENT"), made this 31st day of
January 1997, is entered into by RECEPTOR TECHNOLOGIES, INC., a Delaware
corporation with its principal place of business at 276 East Allen Street,
Winooski, Vermont 05404 (the "COMPANY"), and MARK R. BRANN, residing at 25
Cavendish Cove Road, South Hero, Vermont 05486 (the "OFFICER").

         The Company desires to employ the Officer, and the Officer desires to
be employed by the Company. In consideration of the mutual covenants and
promises contained herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged by the parties hereto,
the parties agree as follows:

         1. TERM OF EMPLOYMENT. The Company hereby agrees to employ the Officer,
and the Officer hereby accepts employment with the Company, upon the terms set
forth in this Agreement until such employment is terminated in accordance with
the provisions of Section 4 (the "EMPLOYMENT PERIOD").

         2. TITLE; CAPACITY. The Officer shall serve as President and Chief
Scientific Officer or in such other position or positions as the Company or its
Board of Directors (the "BOARD") may determine from time to time. The Officer
shall be based initially at the Company's headquarters in Winooski, Vermont. The
Officer shall be subject to the supervision of, and shall have such authority as
is delegated to him by, the Board or such officer of the Company as may be
designated by the Board.

         The Officer hereby accepts such employment and agrees to undertake the
duties and responsibilities inherent in such position and such other duties and
responsibilities as the Board or its designee shall from time to time reasonably
assign to him. Subject to the next paragraph of this Section 2, the Officer
agrees to devote his entire business time, attention and energies to the
business and interests of the Company during the term of his employment with the
Company (subject to the right of the Officer to devote up to 20% of his business
time, energies and attention to other positions PROVIDED THAT such positions
otherwise conform to the provisions of this paragraph and PROVIDED FURTHER that
the Officer's devotion of time to such other positions shall not be to the
detriment of the Company's material interests). The Officer shall not engage in
any other business activity or service in any industry, trade, professional,
governmental or academic position during the term of this Agreement which is
competitive with the business of the Company or which the Officer reasonably
expects would be detrimental to, or have an adverse effect on, the Company. The
other positions currently held by the Officer are described on SCHEDULE A
hereto. The Officer shall provide written notice to the Company of each other
position he accepts during the term of his employment with the Company. If the
Board determines that the Officer's decision to hold such position is not in the
best interests of the Company, then the Board shall, within 60 days of receipt
of written notice from the Officer, notify the Officer that the Company wishes
the Officer to resign from such position and the Officer shall, within 60 days
of receipt of such notice, resign such position.

                                    1.

<PAGE>

         Notwithstanding the other provisions of this Section 2, the Officer
may, for the period ending April 15, 1997, devote more than 20% of his business
time, energies and attention other positions set forth on SCHEDULE A attached
hereto in connection with his transition from those positions, PROVIDED THAT
such positions otherwise conform to the provisions of the second paragraph of
this Section 2 and PROVIDED FURTHER that the Officer's devotion of time to such
other positions shall not be to the detriment of the Company's material
interests.

         The Officer agrees to abide by the rules, regulations, instructions,
personnel practices and policies of the Company and any changes therein which
may be adopted from time to time by the Company. The Officer acknowledges
receipt of copies of all such rules and policies committed to writing as of the
date of this Agreement.

         3. COMPENSATION AND BENEFITS.

                  3.1 SALARY The Company shall pay the Officer, in twice-monthly
installments, an annual base salary of $160,000 for the one-year period
commencing on the Commencement Date. Such salary shall be subject to adjustment
thereafter as determined by the Board (as so adjusted, the "BASE SALARY").

                  3.2 BONUS. The Officer shall be eligible to receive an annual
bonus in an amount up to 20% of Base Salary (the "ANNUAL BONUS"), which bonus
shall be paid solely at the discretion of the Board based on achievement by the
Officer of reasonable, measurable performance objectives to be established by
the Board of Directors at the commencement of each fiscal year. Each Annual
Bonus, if any, shall be made to the Officer within 90 days after the end of the
fiscal year for which such Annual Bonus is being paid.

                  3.3 BENEFITS. The Officer shall be entitled to participate in
all benefit programs that the Company establishes and makes available to its
Officers, if any, to the extent that the Officer's position, tenure, salary,
age, health and other qualifications make him eligible to participate. The
Officer shall be entitled to four weeks paid vacation per year, to be taken at
such times as may be approved by the Board or its designee.

                  3.4 RELOCATION. The Company may require the Officer to
relocate. In the event that the Officer is required to relocate more than 35
miles from Winooski, Vermont, then (i) the Base Salary shall be increased by an
amount equal to 20% or more, and (ii) the Company shall reimburse Officer for
reasonable moving and travel expenses incurred in relocation of Officer and his
immediate family (upon presentation by the Officer of documentation, expense
statements, vouchers and/or such other supporting information as the Company may
request), and (iii) the Company shall provide the Officer with a loan for the
purchase of a home (the "REAL PROPERTY") in the new location. Such loan shall
not exceed $400,000, less the amount of financing available to the Officer upon
the date of such Officer's relocation from a commercial bank or other sources
available to the Officer on terms and conditions customary to such transactions
(including, without limitation, the assumption by the Officer of personal
liability on the loan and a grant of a first-ranking mortgage interest on the
Real Property), and PROVIDED, FURTHER, that in no event shall the Company be
obligated to extend any loan to the Officer in a principal amount in excess of
the difference between 80% of the value of the Real Property (as assessed by an
independent real estate agent) and the outstanding principal amount of all other

                                     2.

<PAGE>

loans secured by the Real Property. Any loan made by the Company hereunder shall
bear interest at the then Applicable Federal Rate, be subject to a first-ranking
mortgage interest (or, if the Officer shall secure financing as contemplated
above, a mortgage interest subordinate only to any interest held by the source
of such financing) for the benefit of the Company and to the Officer, and shall
be repaid (including all interest thereon) no later than five years after such
loan is extended.

                  3.5 REIMBURSEMENT OF EXPENSES. The Company shall reimburse the
Officer for all reasonable travel, entertainment and other expenses incurred or
paid by the Officer in connection with, or related to, the performance of his
duties, responsibilities or services under this Agreement, upon presentation by
the Officer of documentation, expense statements, vouchers and/or such other
supporting information as the Company may request, PROVIDED, HOWEVER, that the
amount available for such travel, entertainment and other expenses may be fixed
in advance by the Board.

         4. EMPLOYMENT TERMINATION. The employment of the Officer by the Company
pursuant to this Agreement shall terminate upon the occurrence of any of the
following:

                  4.1 At the election of the Company, for cause, immediately
upon written notice by the Company to the Officer. For the purposes of this
Section 4.1, cause for termination shall be deemed to exist upon (a) dishonesty,
gross negligence or misconduct of the Officer, or (b) the conviction of the
Officer of, or the entry of a pleading of guilty or nolo contendere by the
Officer to, any crime involving moral turpitude or any felony;

                  4.2 Thirty days after the death or disability of the Officer.
As used in this Agreement, the term "DISABILITY" shall mean the inability of the
Officer, due to a physical or mental disability, for a period of 90 days,
whether or not consecutive, during any 360-day period to perform the services
contemplated under this Agreement. A determination of disability shall be made
by a physician satisfactory to both the Officer and the Company, PROVIDED THAT
if the Officer and the Company do not agree on a physician, the Officer and the
Company shall each select a physician and these two together shall select a
third physician, whose determination as to disability shall be binding on all
parties;

                  4.3 At the election of either party, upon not less than six
months' prior written notice of termination.

                  4.4 At the election of the Officer upon not less than thirty
days prior written notice for Good Reason. For purposes of this Section 4.5,
"GOOD REASON" shall mean (i) the assignment to the Officer of any duties
inconsistent with the Officer's position as President and Chief Scientific
Officer, or (ii) the failure by the Company to comply with the provisions of
this Agreement, if such failure is not remedied by the Company within fifteen
days after receipt of written notice.

         5. EFFECT OF TERMINATION.

                  5.1 TERMINATION FOR CAUSE OR AT ELECTION OF OFFICER. In the
event the Officer's employment is terminated for cause pursuant to Section 4.1,
or at the election of the Officer pursuant to Section 4.3, the Company shall pay
to the Officer (a) the Base Salary and

                                     3.

<PAGE>

benefits otherwise payable to him under Section 3 through the last day of his
actual employment by the Company, and, (b) at the time that an Annual Bonus,
if any, would be paid for such year, a portion of such Annual Bonus (prorated
from the beginning of the then current fiscal year through the last day of
actual employment).

                  5.2 TERMINATION AS A RESULT OF DEATH OR DISABILITY OR AT
ELECTION OF COMPANY OR BY OFFICER FOR GOOD REASON. In the event of termination
by the Company in accordance with Section 4.2 or Section 4.3 or by the Officer
in accordance with Section 4.4, the Company shall pay the Officer (i)
compensation and benefits which would otherwise be payable to the Officer
through the last day of his actual employment by the Company, and (d)
forty-eight twice-monthly severance payments, each in an amount equal to the
Officer's semi-monthly salary at the time of termination (i.e., 1/48th of the
Base Salary), plus benefits, and (iii) at the time that an Annual Bonus, if any,
would be paid for the year during which such termination occurs, the full amount
of such Annual Bonus as would have been paid to him if he had remained in the
employ of the Company through the end of such year.

                  5.3 SURVIVAL. The provisions of Sections 6 and 7 shall survive
the termination of the Officer's employment by the Company.

         6. NON-COMPETE.

                  (a) During the Employment Period and (i) any period of time
subsequent to the Employment Period in which the Officer is receiving severance
payments pursuant to Section 5.2 above, (ii) unless the Officer leaves
employment with the Company for Good Reason, for an additional one-year period
commencing at the end of the time period described in (i) above, (iii) if the
Officer leaves employment with the Company for cause pursuant to Section 4.1
above, for a two-year period commencing at the end of the Employment Period, and
(iv) during any period of time that the Officer is serving as a consultant to
the Company, the Officer will not directly or indirectly, anywhere in the world:

                           (i) as an individual proprietor, partner,
stockholder, officer, Officer, director, joint venturer, investor, lender, or in
any other capacity whatsoever (other than as the holder of not more than one
percent (1%) of the total outstanding stock of a publicly held company), engage
in any business of materially the same nature as the Company's business,
including, without limitation, the business of researching, developing,
producing, marketing or selling products based on receptor-transfected mammalian
cells developed or being developed, produced, marketed or sold by the Company
while the Officer was employed by the Company; or

                           (ii) recruit, solicit or induce, or attempt to
induce, any Officer or Officers of the Company to terminate their employment
with, or otherwise cease their relationship with, the Company; or

                           (iii) solicit, divert or take away, or attempt to
divert or to take away, the business or patronage of any of the clients,
customers or accounts, or prospective clients, customers or accounts, of the
Company which were contacted, solicited or served by the Officer while employed
by the Company.

                                     4.

<PAGE>

                  (b) If any restriction set forth in this Section 6 is found by
any court of competent jurisdiction to be unenforceable because it extends for
too long a period of time or over too great a range of activities or in too
broad a geographic area, it shall be interpreted to extend only over the maximum
period of time, range of activities or geographic area as to which it may be
enforceable.

                  (c) The restrictions contained in this Section 6 are necessary
for the protection of the business and goodwill of the Company and are
considered by the Officer to be reasonable for such purpose. The Officer agrees
that any breach of this Section 6 will cause the Company substantial and
irrevocable damage and therefore, in the event of any such breach, in addition
to such other remedies which may be available, the Company shall have the right
to seek specific performance and injunctive relief.

                  (d) In the event the Officer creates, discovers or is
presented with an opportunity to engage in a business activity in which the
Company might reasonably wish to engage, the Officer shall promptly notify the
Board of Directors of the Company in writing of such opportunity. Unless
otherwise limited under the terms of this Agreement, in the event the Company
does not elect to pursue or evaluate the feasibility of such opportunity within
thirty (30) days after receipt by the Company of such notice, the Officer may
pursue such opportunity.

         7. REPRESENTATION OF OFFICER. As of the date of this Agreement, and
except for unreimbursed expenses and accrued but unpaid salary amounts, the
Officer represents and warrants to the Company that, (i) the Officer has no
claims or causes of action against the Company, whether arising out of his
employment with the Company or otherwise, and (ii) no facts or circumstances
exist which, with the giving of notice or passage of time (or both) would give
rise to a claim or cause of action by the Officer against the Company.

         8. ASSIGNMENT OF DISCOVERIES AND WORKS.

                  (a) The Officer will promptly disclose and assign to the
Company, without charge to it, all rights to discoveries and works which the
Officer may make or conceive, either solely or jointly with others, during the
time of employment with the Company and which relate to the Company's
activities.

                  (b) The Officer agrees that any discovery or work (including,
without limitation, any invention, technical improvement, process or drawing)
(i) which the Officer may disclose to anyone within one year after the
termination of employment with the Company or (ii) which is reduced to tangible
form, such as by a model, a drawing, or a written description, within one year
after termination of employment with the Company, or (iii) for which the Officer
may file application for letters patent or registration of copyright within one
year after the termination of employment with the Company, or (iv) which is
reduced to practice within one year after the termination of employment with the
Company, shall be presumed to have been made and conceived during the period of
employment with the Company; PROVIDED, HOWEVER, that if the Officer proves by
corroborated documentation that any discovery it or work was in fact conceived
and made after termination of employment, then such presumption shall not apply
to that discovery or work.

                                     5.

<PAGE>

                  (c) The Officer will protect the aforesaid discoveries and
works as part of the Company's trade secrets and confidential information.
Nothing in this agreement grants to the Officer any ownership rights to any of
the Company's trade secrets and confidential information or any rights to use
them in any form, except for uses authorized by the Company in furtherance of
the Company's interests.

                  (d) Without charge to the Company, but without expense to the
Officer, the Officer will execute and deliver to the Company such papers,
including applications and assignments, as may be presented to him for the
purpose of obtaining patents, copyrights or other protection for the aforesaid
discoveries and works in any and all countries. The Officer further agrees to
cooperate with and assist in the Company's efforts to establish and maintain the
Company's rights and benefits in the aforesaid discoveries and works, and, if
such cooperation and assistance is required after termination of employment with
the Company, the Company will reimburse the Officer for his reasonable expenses.

         9. CONFIDENTIALITY.

                  (a) During the Officer's employment with the Company the
Officer will not use or disclose any of the Company's trade secrets and
confidential information, except as authorized by the Company in furtherance of
the Company's interests. The Officer further agrees to cooperate with and assist
in the Company's efforts to protect its trade secrets and confidential
information. Pursuant to this end, the Officer agrees never to remove any
tangible materials relating to the Company's trade secrets and confidential
information from the Company's premises, except as authorized b the Company in
furtherance of the Company's interests.

                  (b) After the termination of the Officer's employment with the
Company the Officer will not use or disclose any of the Company's trade secrets
and confidential information except, and only, to the extent such information:

                           (i) becomes part of the public domain other than
through a breach of this Agreement, or

                           (ii) is disclosed to the Officer by a third party who
is entitled to receive and disclose such information.

                  (c) For purposes of this Section 9, the Company's "TRADE
SECRETS AND CONFIDENTIAL INFORMATION" include, without limitation, (i) matters
of a technical nature, such as scientific, trade and engineering secrets,
know-how, formulae, secret processes or machines, inventions, technical
improvements, drawings, designs, computer programs and research projects, (ii)
matters of a business nature, such as information about costs, profits, markets,
sales and lists of customers, and (iii) plans for the Company's future
development.

         10. RETURN OF TANGIBLE MATERIALS. Upon termination of employment with
the Company, or upon Company request, the Officer will return to the Company all
the tangible materials which were obtained from the Company, or which were
purchased at the Company's expense, or which were prepared by the Officer during
the time of employment with the Company and relate to the Company's activities.
For purposes of this Section 10, "TANGIBLE

                                     6.

<PAGE>

MATERIALS" include, without limitation, tools, papers, documents, memoranda,
notes, notebooks, books, records, manuals, sketches, drawings, blueprints,
computer software, designs, forms, price lists, brochures, samples, and
customer lists, including all copies of such materials.

         11. OBLIGATIONS ABSOLUTE. The obligations of the Officer under Sections
6, 8, 9 and 10 of this Agreement are absolute and are not subject to, nor shall
they be affected by, any rights of set-off or claims by the Officer against the
Company.

         12. NOTICES. All notices required or permitted under this Agreement
shall be in writing and shall be deemed effective upon personal delivery or upon
deposit in the United States Post Office, by registered or certified mail,
postage prepaid, addressed to the other party at the address shown above, or at
such other address or addresses as either party shall designate to the other in
accordance with this Section 7.

         13. PRONOUNS. Whenever the context may require, any pronouns used in
this Agreement shall include the corresponding masculine, feminine or neuter
forms, and the singular forms of nouns and pronouns shall include the plural,
and vice versa.

         14. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement.
Notwithstanding the foregoing, the Agreement, dated January 31, 1997 between the
Company and the Officer shall remain in full force and effect.

         15. AMENDMENT. This Agreement may be amended or modified only by a
written instrument executed by both the Company and the Officer.

         16. GOVERNING LAW. This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the State of Delaware.

         17. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
inure to the benefit of both parties and their respective successors and
assigns, including any corporation with which or into which the Company may be
merged or which may succeed to its assets or business, PROVIDED, HOWEVER, that
the obligations of the Officer are personal and shall not be assigned by him.

         18. MISCELLANEOUS.

                  18.1 No delay or omission by the Company in exercising any
right under this Agreement shall operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion shall be effective
only in that instance and shall not be construed as a bar or waiver of any right
on any other occasion.

                  18.2 The captions of the sections of this Agreement are for
convenience of reference only and in no way define, limit or affect the scope or
substance of any section of this Agreement.

                                      7.

<PAGE>

                  18.3 In case any provision of this Agreement shall be invalid,
illegal or otherwise unenforceable, the validity, legality and enforceability of
the remaining provisions shall in no way be affected or impaired thereby.

                                      8.

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year set forth above.

                                      RECEPTOR TECHNOLOGIES, INC.

                                      By: /s/ Mark R. Brann
                                         ---------------------------------------

                                      Title:  President
                                            ------------------------------------

                                      Officer

                                      /s/ Mark R. Brann
                                      ------------------------------------------
                                      MARK R. BRANN

                           [SIGNATURE PAGE TO EMPLOYMENT AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]